09/05/2026
🔥Xeligekimab🔥 vs other IL‑17A inhibitors in patients with moderate‑to‑severe plaque psoriasis – comparable early response but stronger long‑term skin clearance and better infection‑related safety!
✅At week 12, PASI 75/90/100 responses are similar between xeligekimab and both comparators, with only a non‑significant numerical trend toward higher PASI 75 with secukinumab.
✅At week 52, xeligekimab achieves significantly higher PASI 100 vs secukinumab (57.8% vs 42.1%, p=0.005) and better DLQI 0/1 (68.8% vs 47.5%, p